Acarbose: oral anti-diabetes drug with additional cardiovascular benefits (Q37076275)

18 August 2017

1 reference

title

Acarbose: oral anti-diabetes drug with additional cardiovascular benefits (English)

1 reference

18 August 2017

1 reference

1

Markolf Hanefeld

1 reference

18 August 2017

Frank Schaper

2

1 reference

18 August 2017

1 February 2008

1 reference

Expert Review of Cardiovascular Therapy

18 August 2017

1 reference

18 August 2017

6

1 reference

18 August 2017

153-163

1 reference

18 August 2017

2

1 reference

Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Postprandial glucose regulation and diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Adiposity, inflammation and hyperglycaemia in rural and urban Indian men: Coronary Risk of Insulin Sensitivity in Indian Subjects (CRISIS) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Insulin resistance and the metabolic syndrome--or the pitfalls of epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Effect of acarbose on insulin sensitivity in elderly patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: Dose-time-response relationships in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Acarbose treatment does not change the habitual diet of patients with Type 2 diabetes mellitus. The Finnish Acargbos Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Acarbose in the treatment of type I diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

The DREAM trial – Authors' reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

Post-meal coagulation activation in diabetes mellitus: the effect of acarbose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.2.153

21 January 2018

Identifiers

DOI

10.1586/14779072.6.2.153

1 reference

18 August 2017

1 reference

PubMed ID

18248270